NextCure(NXTC) - 2024 Q1 - Quarterly Results

Exhibit 99.1 NextCure Provides Business Update and Reports First Quarter 2024 Financial Results – Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 – Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting – Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE, Md. – May 2, 2024 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing nov ...